Personalizing Diabetes Therapy: Enhancing Traditional A1C Results with GlycoMark®

Effective diabetes management relies heavily on the ability to monitor glycemic control accurately over time. For decades, the measurement of Hemoglobin A1C (HbA1c) has served as the gold standard for assessing long-term glucose regulation. By reflecting average blood glucose levels over a period of two to three months, A1C provides clinicians with a foundational metric for diagnosing diabetes and evaluating treatment efficacy. However, as precision medicine advances, it has become increasingly evident that A1C alone does not provide a complete physiological picture. To achieve optimal glycemic control and minimize the risk of vascular complications, healthcare providers are turning to complementary biomarkers. Among these, GlycoMark® testing offers significant clinical utility by revealing hyperglycemic excursions that traditional A1C testing may obscure.

The Limitations of A1C in Isolation

Hemoglobin A1C represents a weighted average of glucose levels. While invaluable, an average can mask significant volatility. Two patients with identical A1C values of 7.5% may present with vastly different glycemic profiles. One patient may exhibit stable glucose levels with minimal fluctuation, while the other experiences frequent episodes of hypoglycemia followed by severe postprandial hyperglycemia. These rapid fluctuations, particularly postprandial spikes, are associated with increased oxidative stress and endothelial dysfunction, contributing to microvascular and macrovascular complications.

Furthermore, A1C reflects glucose exposure over approximately 90 days. It is not sensitive to recent changes in therapy or diet occurring within the last one to two weeks. For physicians managing complex cases within Primary Care and Internal Medicine, reliance on A1C alone may delay necessary therapeutic adjustments. Recognizing these limitations is the first step toward a more personalized approach to diabetes care.

The Science of GlycoMark®: Measuring 1,5-Anhydroglucitol

The GlycoMark® test measures serum levels of 1,5-anhydroglucitol (1,5-AG), a naturally occurring monosaccharide found in food. Under normal physiological conditions, 1,5-AG is filtered by the kidneys and nearly completely reabsorbed by the renal tubules, maintaining stable levels in the blood. However, the reabsorption of 1,5-AG is competitively inhibited by glucose.

When blood glucose levels exceed the renal threshold—typically around 180 mg/dL—excess glucose blocks the reabsorption of 1,5-AG. Consequently, 1,5-AG is excreted in the urine, and serum levels drop rapidly. Therefore, a lower level of 1,5-AG in the blood indicates a higher frequency and severity of hyperglycemic spikes. Unlike A1C, which looks back months, GlycoMark® reflects glycemic variability and postprandial glucose peaks over the preceding one to two weeks. This shorter window allows pathologists and clinicians to assess the immediate impact of therapeutic interventions.

Targeting Postprandial Hyperglycemia

Postprandial hyperglycemia (PPH) is a distinct risk factor for cardiovascular disease and is often the first sign of dysregulation in early diabetes. Traditional fasting glucose tests and A1C often fail to capture PPH. A patient may have a fasting glucose within normal limits and a moderately controlled A1C, yet still experience damaging glucose spikes after meals.

Utilizing GlycoMark® allows providers to specifically identify these excursions. By detecting glucose peaks above 180 mg/dL, the test provides actionable data that can influence decisions regarding mealtime insulin dosing or the initiation of therapies specifically targeting post-meal glucose. This level of granularity is essential for clinical laboratory interpretation and subsequent treatment modification.

Clinical Synergy: Combining A1C and GlycoMark®

The most effective use of GlycoMark® is not as a replacement for A1C, but as a synergistic companion. When used together, these tests provide a comprehensive view of a patient’s glycemic status—covering both the long-term average and the short-term variability.

This dual-marker approach is particularly useful in identifying “A1C discordance.” This phenomenon occurs when a patient’s A1C suggests adequate control (e.g., <7.0% or <8.0%), but the patient continues to experience symptoms of hyperglycemia or incipient complications. In such scenarios, a low GlycoMark® result reveals that despite a good average, the patient is experiencing significant peaks, likely offset by periods of hypoglycemia or lower baseline levels. This insight prevents the false assurance that can come from a “good” A1C result and prompts a more targeted review of diet and medication timing.

Physicians can order these tests seamlessly through platforms like PathConnect™, ensuring that the integration of advanced biomarkers into routine practice does not disrupt workflow efficiency.

Indications for Use in Therapy Management

Incorporating GlycoMark® into the diabetes testing menu is advantageous in several specific clinical scenarios:

Assessing Treatment Efficacy Quickly

Because GlycoMark® reflects glucose control over a 1-2 week period, it is ideal for monitoring patients shortly after a medication change. Unlike A1C, which requires months to show significant change, 1,5-AG levels respond rapidly. This allows for faster titration of drugs, reducing clinical inertia.

Managing Moderate Control

Patients with A1C levels between 6.5% and 8.0% often have the highest contribution of postprandial glucose to their overall hyperglycemic exposure. In this range, targeting fasting glucose yields diminishing returns. GlycoMark® helps identify if PPH is the barrier preventing the patient from reaching their A1C goal.

Monitoring in Specific Conditions

Certain conditions, such as hemolytic anemia or hemoglobinopathies, can render A1C results inaccurate due to altered red blood cell turnover. Since 1,5-AG is not linked to hemoglobin, GlycoMark® provides a reliable alternative marker for glycemic monitoring in these populations. This reliability aligns with the rigorous standards maintained by PathGroup’s medical leadership.

PathGroup’s Commitment to Endocrine Health

The management of endocrine disorders requires precise, reliable, and timely diagnostic data. PathGroup supports healthcare providers with a comprehensive menu of services tailored to endocrinology, including A1C, C-Peptide, Insulin, and GlycoMark®. Operating 24 hours a day, seven days a week, the laboratory ensures that results are delivered with industry-leading turnaround times, empowering physicians to make informed decisions without delay.

PathGroup distinguishes itself through a physician-led model, where medical leadership is deeply integrated into laboratory operations. With access to over 190 pathologists and scientific specialists, requesting physicians can discuss complex cases and interpretation strategies directly with experts. This collaborative approach ensures that diagnostic data is not just a number on a page, but a tool for improving patient outcomes.

Furthermore, the integration of technology solutions such as MyResults™ allows patients to access their own lab data, fostering engagement in their own care plans. When patients understand the difference between their average glucose (A1C) and their glucose spikes (GlycoMark®), adherence to dietary and pharmacological recommendations often improves.

Integrating Advanced Diagnostics for Better Outcomes

The shift toward personalized medicine in diabetes care necessitates a move beyond one-size-fits-all metrics. By utilizing GlycoMark® alongside traditional A1C testing, clinicians gain a multidimensional view of glycemic control that accounts for the dangerous variability of glucose spikes. This dual approach facilitates more timely therapeutic adjustments, better targeting of postprandial hyperglycemia, and ultimately, a reduction in the risk of diabetes-related complications.

PathGroup delivers full-service diagnostic excellence through anatomic, clinical, and molecular pathology—backed by physician leadership and cutting-edge digital technologies. With 24/7 operations and rapid turnaround times, PathGroup empowers hospitals and physicians with faster, more accurate results that drive better patient outcomes. Trusted by over 250 hospitals across 25 states, this integrated approach ensures seamless testing, expert interpretation, and a commitment to clinical precision at every step.

For more updates and information, please visit the following social media pages: Google, Facebook, and LinkedIn.